Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Tuberous Sclerosis 4Seizures 3Lennox Gastaut Syndrome 3Epilepsies, Myoclonic 3Anxiety Disorders 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Prostatic Neoplasms 1Parasomnias 1Pain 1Neoplasms 1Nausea 1Marijuana Abuse 1Liver Cirrhosis 1Glioblastoma 1Epilepsy 1Colorectal Neoplasms 1Colonic Neoplasms 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Pain 1Breast Neoplasms 1Breast Carcinoma In Situ 1Behavior 1

Interventions

Bevacizumab 120Fluorouracil 90Cetuximab 84Leucovorin 82Oxaliplatin 80pembrolizumab 70Irinotecan 66Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26HMPL-013 26Standard of Care 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19tislelizumab 18atezolizumab 18Trifluridine 18Cisplatin 18balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Cannabidiol × 1 year × Clear all
NCT07167446 2025-10-22

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡